U.S.-based Boulevard Bio is paying $20 million upfront (PDF) to China’s Metis TechBio for the global rights to a trispecific T-cell engager (TCE) for autoimmune diseases. The preclinical asset, dubbed ...
-- Round led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor, Aditum Bio -- --LBL-051’s ability to reset the immune system is supported by recent preclinical ...
The Universitat Autònoma de Barcelona (UAB) and the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) have developed a new generation of wireless piezoelectric microdevices capable of ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...
Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. Tuesday, the FDA approved the ...
CHICAGO & MILPITAS, Calif.--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced ...
A Science Immunology Review explains how memory B cells acquire diverse molecular, epigenetic, and tissue-specific programs ...
Many blood cancers can be treated with a potentially curative stem cell transplant, but this procedure introduces a serious complication risk that can become deadly. A new type of cell therapy gives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results